Alex Zhavoronkov (Insilico)
February 24, 2021 09:00 AM EST
AI

In­sil­i­co preps first can­di­date for IND stud­ies, hop­ing to launch tri­al in IPF by end of 2021

Max Gelman

Senior Editor

Over the last sev­er­al years, Alex Zha­voronkov has turned In­sil­i­co in­to one of the most well-con­nect­ed AI biotechs out there. Now, the Hong Kong-based com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times